Distribution of chimeric antigen receptor-modified T cells against CD19 in B-cell malignancies

Abstract Background The unprecedented efficacy of chimeric antigen receptor T (CAR-T) cell immunotherapy CD19 + B-cell malignancies has opened a new and useful way for the treatment malignant tumors. Nonetheless, there are still formidable challenges in field CAR-T therapy, such as biodistribution cells vivo. Methods NALM-6, human acute lymphoblastic leukemia (B-ALL) line, was used target cells. were injected into mice model with or without Then we measured distribution mice. In addition, an exploratory clinical trial conducted 13 r/r non-Hodgkin lymphoma (B-NHL) patients, who received infusion. dynamic changes patient blood parameters over time after infusion detected by qPCR flow cytometry. Results proliferated being infused within 2 weeks. However, did not increase significantly presence weeks infusion, but expanded at week 6. trial, found that peaked 7–21 days lasted 420 peripheral patients. Simultaneously, mild side effects observed, which could be effectively controlled months these Conclusions can expand themselves mice, persist long NHL patients serious effects. Trial registration date is May 17, 2018 numbers NCT03528421 .